VTRS
Viatris, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website viatris.com
- Employees(FY) 38000
- ISIN US92556V1061
Performance
-1.38%
1W
-0.19%
1M
+15.8%
3M
+24.33%
6M
+23.23%
YTD
+35.76%
1Y
Profile
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Technical Analysis of VTRS 2024-12-12
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-06 11:03
- 2024-12-02 19:30
Mapi Pharma is Seeking New Depot Product Partnerships(Globenewswire)
- 2024-11-22 09:02
- 2024-11-21 08:51
- 2024-11-13 11:28
- 2024-11-11 11:01
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m(Pharmaceutical Technology)
- 2024-11-08 02:14
- 2024-11-07 17:02
- 2024-11-07 16:46
Analyst Report: Viatris Inc.(Morningstar Research)
- 2024-11-07 11:16
- 2024-11-07 09:30
- 2024-11-07 08:25
- 2024-11-07 08:14
- 2024-11-07 06:59
- 2024-11-07 04:02
- 2024-11-06 18:27
Viatris: Q3 Earnings Snapshot(Yahoo Finance)
- 2024-11-06 17:59
- 2024-11-05 15:00
- 2024-11-05 06:59
Viatris Announces Third Quarter 2024 Dividend(PR Newswire)
- 2024-11-04 17:59
Viatris Announces Third Quarter 2024 Dividend(Prnewswire)
- 2024-11-04 13:44
- 2024-11-04 09:16
- 2024-10-30 00:00
- 2024-10-29 12:00
- 2024-10-29 09:00
- 2024-10-28 21:00
- 2024-10-28 14:00
- 2024-10-17 07:15
- 2024-10-17 05:55
Lexicon partners Viatris for global expansion of sotagliflozin(Pharmaceutical Technology)
- 2024-10-17 04:35
Page 1 of 10
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.